Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Parkinson's Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Parkinson's Disease
Parkinson's Disease Therapeutics under Development by Companies
Parkinson's Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Parkinson's Disease Therapeutics - Products under Development by Companies
Parkinson's Disease Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Parkinson's Disease Therapeutics Development
Genzyme Corporation
Kyowa Hakko Kirin Co., Ltd.
Abbott Laboratories
Biogen Idec Inc.
NsGene A/S
AstraZeneca PLC
Daiichi Sankyo Company, Ltd
Orion Corporation
Pfizer Inc.
Hadasit Medical Research Services & Development Ltd
ArmaGen Technologies, Inc.
UCB S.A.
BIOPROJET SCR
Varinel, Inc.
Mt Cook Pharma. Inc.
SK Bio-Pharmaceuticals
Cellzome, Inc.
Immune Technologies and Medicine
PharmaNeuroBoost N.V.
UNeMed
Parkinson's Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
IPX066 - Drug Profile
Posiphen - Drug Profile
V1512 - Drug Profile
PD-02 - Drug Profile
ProSavin - Drug Profile
SYN-115 - Drug Profile
Neupro - Drug Profile
Dipraglurant - Drug Profile
AFQ056 - Drug Profile
OS-320 - Drug Profile
Piclozotan - Drug Profile
Neu-120 - Drug Profile
AAV-GAD gene therapy - Parkinson's disease - Drug Profile
Northera - Drug Profile
Pimavanserin Tartrate - Drug Profile
CERE-120 - Drug Profile
BIA 9-1067 - Drug Profile
SYN-118 - Drug Profile
Serdaxin - Drug Profile
XP-21279 - Drug Profile
VR040 - Drug Profile
MitoQ - Drug Profile
Stalevo - Drug Profile
Safinamide - Drug Profile
Apomorphine - Drug Profile
KW-6500 - Drug Profile
KW-6002 - Drug Profile
KW-6002 - Drug Profile
Naluzotan - Drug Profile
sNN0031 - Drug Profile
Memantine - Drug Profile
Caffeine - Drug Profile
Cogane - Drug Profile
Duodopa - Drug Profile
Duodopa - Drug Profile
Transdermal Nicotine - Drug Profile
Donepezil - Drug Profile
Preladenant - Drug Profile
GDNF - Drug Profile
Ritalin - Drug Profile
Deferiprone - Drug Profile
Dynacirc CR - Drug Profile
Talampanel - Drug Profile
Exelon - Drug Profile
Coenzyme Q10 - Drug Profile
Accordion Pill Carbidopa/Levodopa - Drug Profile
Inosine - Drug Profile
NLX-P101 - Drug Profile
Coenzyme Q10 + Vitamin E - Drug Profile
ND0611 - Drug Profile
Motiva - Drug Profile
Pitolisant - Drug Profile
Dynacirc CR - Drug Profile
GM1 Ganglioside - Drug Profile
Exendin-4 - Drug Profile
KW-6002 - Drug Profile
Venlafaxine - Drug Profile
Glutathione - Drug Profile
GM602 - Drug Profile
Filgrastim - Drug Profile
NST0021 - Drug Profile
Pioglitazone - Drug Profile
Duodopa - Drug Profile
ACP-103 - Drug Profile
Chantix - Drug Profile
Zolpidem - Drug Profile
Edaravon - Drug Profile
Parkinson's Disease Therapeutics - Drug Profile Updates
Parkinson's Disease Therapeutics - Discontinued Products
Parkinson's Disease Therapeutics - Dormant Products
Parkinson's Disease - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Parkinson's Disease, H1 2012
Products under Development for Parkinson's Disease - Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Development by Companies, H1 2012 (Contd..5)
Number of Products under Development by Companies, H1 2012 (Contd..6)
Number of Products under Development by Companies, H1 2012 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Development by Companies, H1 2012 (Contd..5)
Products under Development by Companies, H1 2012 (Contd..6)
Products under Development by Companies, H1 2012 (Contd..7)
Products under Development by Companies, H1 2012 (Contd..8)
Products under Development by Companies, H1 2012 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Genzyme Corporation, H1 2012
Kyowa Hakko Kirin Co., Ltd., H1 2012
Abbott Laboratories, H1 2012
Biogen Idec Inc., H1 2012
NsGene A/S, H1 2012
AstraZeneca PLC, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Merck & Co., Inc., H1 2012
Oxford BioMedica plc, H1 2012
Sangamo BioSciences, Inc., H1 2012
Vectura Group plc, H1 2012
XenoPort, Inc., H1 2012
BioLineRx, Ltd., H1 2012
Novartis AG, H1 2012
EnVivo Pharmaceuticals, H1 2012
Depomed, Inc., H1 2012
Elan Corporation, plc, H1 2012
H Lundbeck A/S, H1 2012
Orion Corporation, H1 2012
Pfizer Inc., H1 2012
Hadasit Medical Research Services & Development Ltd, H1 2012
IMPAX Laboratories, Inc., H1 2012
Vernalis plc, H1 2012
BrainStorm Cell Therapeutics Inc., H1 2012
NuPathe Inc., H1 2012
Aeolus Pharmaceuticals, Inc., H1 2012
Addex Pharmaceuticals, H1 2012
Evotec Aktiengesellschaft, H1 2012
Hollis-Eden Pharmaceuticals, Inc., H1 2012
Amicus Therapeutics, Inc., H1 2012
Living Cell Technologies Limited, H1 2012
Lixte Biotechnology Holdings, Inc., H1 2012
ReGenX Biosciences, LLC, H1 2012
Neuren Pharmaceuticals Limited, H1 2012
Neurologix, Inc., H1 2012
NeuroSearch A/S, H1 2012
Cortex Pharmaceuticals, Inc., H1 2012
ACADIA Pharmaceuticals Inc., H1 2012
Adolor Corp., H1 2012
Chelsea Therapeutics, Inc., H1 2012
CombinatoRx, Incorporated, H1 2012
ProteoTech, Inc., H1 2012
Phytopharm Plc, H1 2012
SYGNIS Pharma AG, H1 2012
Prana Biotechnology Limited, H1 2012
Green Cross Corporation, H1 2012
AnGes MG, Inc., H1 2012
Biotie Therapies Corp., H1 2012
Allon Therapeutics Inc., H1 2012
Neurim Pharmaceuticals (1991) Ltd., H1 2012
Proximagen Neuroscience plc., H1 2012
Newron Pharmaceuticals S.p.A., H1 2012
Amsterdam Molecular Therapeutics BV, H1 2012
Rexahn Pharmaceuticals, Inc., H1 2012
Oryzon, H1 2012
The Avicena Group, Inc., H1 2012
M et P Pharma AG, H1 2012
TauRx Therapeutics Ltd, H1 2012
Antipodean Pharmaceuticals, Inc., H1 2012
Ceregene, Inc., H1 2012
AFFiRiS AG, H1 2012
Noscira, S.A., H1 2012
Accera, Inc., H1 2012
Upsher-Smith Laboratories, Inc., H1 2012
Osmotica Pharmaceutical Corp., H1 2012
Snowdon Inc., H1 2012
Domain Therapeutics, H1 2012
BioMAS Ltd., H1 2012
Wellstat Therapeutics Corporation, H1 2012
Trophos SA, H1 2012
Intec Pharma ltd., H1 2012
InterMed Discovery GmbH, H1 2012
MedGenesis Therapeutix Inc., H1 2012
AngioChem Inc., H1 2012
NeuroNova AB, H1 2012
BioArctic Neuroscience AB, H1 2012
Indus Biotech Private Limited, H1 2012
Affichem, H1 2012
QR Pharma, Inc., H1 2012
NeuroNascent, Inc., H1 2012
KineMed, Inc., H1 2012
QRxPharma Limited, H1 2012
Omeros Corporation, H1 2012
Xencor, Inc., H1 2012
Intra-Cellular Therapies, Inc., H1 2012
Obio Pharmaceutical Holdings Limited., H1 2012
Bial Group, H1 2012
SanBio, Inc., H1 2012
M's Science Corporation, H1 2012
Stelic Institute & Co., H1 2012
Cellceutix Pharmaceuticals, Inc., H1 2012
Heptares Therapeutics Ltd., H1 2012
Signum Biosciences, Inc., H1 2012
Neuraltus Pharmaceuticals, Inc., H1 2012
ArmaGen Technologies, Inc., H1 2012
UCB S.A., H1 2012
BIOPROJET SCR, H1 2012
Varinel, Inc., H1 2012
Mt Cook Pharma. Inc., H1 2012
SK Bio-Pharmaceuticals, H1 2012
Cellzome, Inc., H1 2012
Immune Technologies and Medicine, H1 2012
PharmaNeuroBoost N.V., H1 2012
UNeMed, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Parkinson's Disease Therapeutics - Drug Profile Updates
Parkinson's Disease Therapeutics - Discontinued Products
Parkinson's Disease Therapeutics - Discontinued Products (Contd..1)
Parkinson's Disease Therapeutics - Discontinued Products (Contd..2)
Parkinson's Disease Therapeutics - Dormant Products
Parkinson's Disease Therapeutics - Dormant Products (Contd..1)
Parkinson's Disease Therapeutics - Dormant Products (Contd..2)
Parkinson's Disease Therapeutics - Dormant Products (Contd..3)
Parkinson's Disease Therapeutics - Dormant Products (Contd..4)
Parkinson's Disease Therapeutics - Dormant Products (Contd..5)
Parkinson's Disease Therapeutics - Dormant Products (Contd..6)
Parkinson's Disease Therapeutics - Dormant Products (Contd..7)

List of Figures
Number of Products under Development for Parkinson's Disease, H1 2012
Products under Development for Parkinson's Disease - Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Click here to open the POPUP